Not intended for UK and US Media - Stroke Prevention in Patients with Atrial Fibrillation:
Bayer’s Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation

Not intended for U.S. and UK Media (LBA #385) - Results of pivotal Phase III study in patients with metastatic colorectal cancer:
Positive Phase III Data on Bayer’s Investigational Drug Regorafenib Show Significant Increase in Overall Survival

Not intended for US Media: Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI):
Phase III Data of Bayer’s Regorafenib in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Oral Presentation at 2012 ASCO-GI Congress